Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the ‘real-world’

References

• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Pleyer L, Dohner H, Dombret H, et al. Azacitidine for front-line therapy of patients with AML: reproducible efficacy established by direct comparison of international phase 3 trial data with registry data from the Austrian Azacitidine Registry of the AGMT Study Group. Int J Mol Sci. 2017;18(2):E415.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Bernal T, Martinez-Camblor P, Sanchez-Garcia J, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29(9):1875–1881.
   PubMed Web of Science ®Google Scholar
• Dinmohamed AG, van Norden Y, Visser O, et al. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Leukemia. 2015;29(12):2449–2451.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403–411.
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the ‘real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. Br J Haematol. 2018;181(6):803–815.
   PubMed Web of Science ®Google Scholar
• Crespo C, Moreno E, Sierra J, et al. Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain. Health Econ Rev. 2013;3(1):28.
   PubMedGoogle Scholar
• Gidwani R, Khan ZM, Fenaux P, et al. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. J Med Econ. 2012;15(1):145–154.
   PubMedGoogle Scholar
• Levy AR, Zou D, Risebrough N, et al. Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes. Curr Oncol. 2013;21(1):e29–e40.
   Web of Science ®Google Scholar
• Seymour JF, Dohner H, Minden MD, et al. Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia. Leuk Lymphoma. 2017;58(6):1412–1423.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
   PubMed Web of Science ®Google Scholar
• The Johns Hopkins University ACG Case-Mix Adjustment System, Version 10. Baltimore (MD): The Johns Hopkins University School of Hygiene and Public Health.
   Google Scholar
• Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99(2):344–351.
   PubMed Web of Science ®Google Scholar
• Buckstein R, Yee K, Wells RA. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline. Cancer Treat Rev. 2011;37(2):160–167.
   PubMed Web of Science ®Google Scholar
• Wells RA, Leber B, Zhu NY, et al. Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence. Curr Oncol. 2013;21(1):44–50.
   Web of Science ®Google Scholar
• Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011;117(12):2697–2702.
   PubMed Web of Science ®Google Scholar
• Cogle CR, Kurtin SE, Bentley TG, et al. The incidence and health care resource burden of the myelodysplastic syndromes in patients in whom first-line hypomethylating agents fail. Oncologist. 2017;22(4):379–385.
   PubMed Web of Science ®Google Scholar
• Bell JA, Galaznik A, Blazer M, et al. Economic burden of patients treated for higher-risk myelodysplastic syndromes (HR-MDS) in routine clinical care in the United States. Pharmacoecon Open. 2019;3(2):237–245.
   PubMed Web of Science ®Google Scholar
• Lindquist KJ, Danese MD, Mikhael J, et al. Health care utilization and mortality among elderly patients with myelodysplastic syndromes. Ann Oncol. 2011;22(5):1181–1188.
   PubMed Web of Science ®Google Scholar
• Powers A, Faria C, Broder MS, et al. Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. Am Health Drug Benefits. 2012;5(7):455–465.
   PubMedGoogle Scholar
• Austin PC, van Walraven C, Wodchis WP, et al. Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada. Med Care. 2011;49(10):932–939.
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
   PubMed Web of Science ®Google Scholar
• Peppercorn JM, Weeks JC, Cook EF, et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet. 2004;363(9405):263–270.
   PubMed Web of Science ®Google Scholar
• Elting LS, Cooksley C, Bekele BN, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006;106(11):2452–2458.
   PubMed Web of Science ®Google Scholar
• Bleyer A. In and out, good and bad news, of generalizability of SWOG treatment trial results. J Natl Cancer Inst. 2014;106(3):dju027.
   PubMedGoogle Scholar
• Eichler HG, Abadie E, Breckenridge A, et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10(7):495–506.
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Lilford RJ, Braunholtz DA, et al. Ethical issues in the design and conduct of randomised controlled trials. Health Technol Assess. 1998, 2(15):i–vi, 1–132.
   PubMedGoogle Scholar
• Unger JM, Barlow WE, Martin DP, et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst. 2014;106(3):dju002.
   PubMedGoogle Scholar
• Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–3327.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN Recommendations from an International Expert Panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–3627.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287–4294.
   PubMed Web of Science ®Google Scholar
• Abel GA, Buckstein R. Integrating frailty, comorbidity, and quality of life in the management of myelodysplastic syndromes. Am Soc Clin Oncol Educ Book. 2016;35:e337–e344.
   PubMedGoogle Scholar
• Buckstein R, Wells RA, Zhu N, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;174(1):88–101.
   PubMed Web of Science ®Google Scholar
• Campitelli MA, Bronskill SE, Hogan DB, et al. The prevalence and health consequences of frailty in a population-based older home care cohort: a comparison of different measures. BMC Geriatr. 2016;16(1):133.
   PubMedGoogle Scholar
• McIsaac DI, Wong CA, Huang A, et al. Derivation and validation of a generalizable preoperative frailty index using population-based health administrative data. Ann Surg. 2018;270(1):102–108.
   Web of Science ®Google Scholar